The Need for Longer Lasting PAD Solutions with DCB Technology
This program outlines the essential need for longer-lasting Peripheral Arterial Disease (PAD) solutions for complex lesions using drug-coated balloon therapy. Join us for this live 60-min panel discussion with leading physician experts describing the latest safety data and their continued practice with the Lutonix™ Drug-Coated Balloon Platform. Highlights include:
- The Latest Safety on Paclitaxel: SWEDEPAD, presented by the National Principal Investigators
- Drug-Eluting Therapy: The critical role it plays in everyday PAD practice
- Real-World Case Applications: The Lutonix™ DCB – The only DCB with options for both .035” and .018” guide platforms on the U.S. Market.
- Dr. George Adams, MD, MHS, MBA, FACC, FSCAI; UNC Rex Healthcare, University of North Carolina; Chapel Hill Medical Center, Raleigh, North CarolinaDr. Gary Ansel, MD, FMCC; Assistant Clinical Professor of Medicine, Department of Internal Medicine, University of Toledo Medical Center, Toledo, Ohio; Chief Medical Officer and President for Healthcare InsightsDr. John Phillips, MD; System Director, OhioHealth Vascular Institute; Medical Director of Endovascular Medicine and Clinical Operations Council Chief of the Heart and Vascular Service Line, Riverside Methodist Hospital, Columbus, OhioProf. Joakim Nordanstig, MD, PhD; Senior Vascular Surgeon and Vascular Researcher, Sahlgranska University Hospital, Gothenburg, SwedenProf. Marten Falkenberg, MD, PhD; Vascular Surgeon, Department of Radiology, Sahlgrenska University Hospital, Gothenburg, Sweden